ArticleBMC health services research2025
Cost-effectiveness analysis of first-line gifitinib plus pemetrexed-platinum-based chemotherapy versus gifitinib monotherapy in EGFR-mutated NSCLC patients with brain metastases.
Article in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeBrain metastases (BrMs) frequently manifest in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the optimal treatment approach for these individuals remains controversial. This study aimed to evaluate the cost-effectiveness of adding pemetrexed-platinum chemotherapy to first-line gefitinib in EGFR-mutant NSCLC patients with BrMs, considering the perspective of the Chinese healthcare system. PATIENTS AND
methodsConstructing a Markov model, we simulated disease progression over a 10-year horizon in 4-week intervals. The model included three main health states: progression-free survival (PFS), progressive disease (PD), and death, along with a temporary PFS health state. Transition probabilities were estimated based on the data from the GAP BRAIN trial. Costs and utilities were collected from local public database and literature. One-way and probabilistic sensitivity analyses were employed to assess the robustness of the model.
resultsIn the base case analysis, adding pemetrexed-platinum chemotherapy to first-line gefitinib resulted in an incremental effectiveness of 0.59 quality-adjusted life years (QALYs) and an increase in healthcare costs by $12,298.51. Consequently, the incremental cost-effectiveness ratio (ICER) amounted to $24,887.67/QALY, which fell below the prespecified willingness-to-pay (WTP) threshold of $37,654.50 per QALY. Deterministic sensitivity analysis indicated that, apart from the utility value of the PFS health state of the gefitinib plus chemotherapy (GPP) group, other parameters exerted minimal influence on the results. The probabilistic sensitivity analysis demonstrated that, at the predefined WTP threshold, the combination of gefitinib and chemotherapy was a cost-effective treatment strategy.
conclusionAdding pemetrexed-platinum chemotherapy to first-line gefitinib for EGFR-mutant NSCLC patients with BrMs in China represented a cost-effective treatment strategy from the perspective of the Chinese healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.